title: (E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
abstract: (E)-3-[[[[6-(2-Carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]methyl]thio]methyl]benzoic acid (11, SB 201993) is a novel, potent LTB4 receptor antagonist. Compound 11 arose from a structure-activity study of a series of trisubstituted pyridines that demonstrated LTB4 receptor antagonist activity. The placement of an additional methylene unit in the sulfur containing chain linking the pyridine and benzoic acid moieties of lead compound 8 (K(i) = 80 nM) resulted in a greater than 10-fold increase in receptor affinity. Additionally, in this new series of compounds, the oxidation state of the sulfur was found to be critical to the activity, i.e., the sulfoxide and sulfone showed substantially lower affinity for the LTB4 receptor. Compound 11 competitively inhibits the binding of [3H]LTB4 to LTB4 receptors on human polymorphonuclear leukocytes with a Ki of 7.1 nM and blocks both the LTB4-induced calcium mobilization and the LTB4-induced degranulation responses in these cells with IC50 values of 131 and 271 nM, respectively. Compound 11 demonstrated oral LTB4 antagonist activity as well as topical antiinflammatory activity in the mouse.
authors.affiliation: Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-0939.
authors.forename: R A
authors.initials: RA
authors.lastname: Daines
authors.forename: P A
authors.initials: PA
authors.lastname: Chambers
authors.forename: D S
authors.initials: DS
authors.lastname: Eggleston
authors.forename: J J
authors.initials: JJ
authors.lastname: Foley
authors.forename: D E
authors.initials: DE
authors.lastname: Griswold
authors.forename: R C
authors.initials: RC
authors.lastname: Haltiwanger
authors.forename: D R
authors.initials: DR
authors.lastname: Jakas
authors.forename: W D
authors.initials: WD
authors.lastname: Kingsbury
authors.forename: L D
authors.initials: LD
authors.lastname: Martin
authors.forename: I
authors.initials: I
authors.lastname: Pendrak
mesh_terms: D001565:Benzoates / Q000737:chemistry* / Q000494:pharmacology; D001667:Binding, Competitive; D002118:Calcium / Q000097:blood; D018360:Crystallography, X-Ray; D003594:Cytoplasmic Granules / Q000187:drug effects; D006801:Humans; D007975:Leukotriene B4 / Q000378:metabolism / Q000494:pharmacology; D015394:Molecular Structure; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D011725:Pyridines / Q000737:chemistry* / Q000494:pharmacology; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D001565:Benzoates; D011725:Pyridines; D018102:Receptors, Leukotriene B4; C083427:(E)-3-((((6-(2-carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid; D007975:Leukotriene B4; D002118:Calcium